Sacubitril valsartan for chronic heart failure

27th May 2016 by Louise Hudman

Sacubitril valsartan for chronic heart failure

This is a new guideline from NICE on when sacubitril valsartan should be used.

Sacubitril valsartan is a combination drug. It includes the angiotensin 2 receptor blocker (ARB), valsartan. It also includes the neprilysin inhibitor, sacubitril. Neprilysin inhibition leads to increased levels of vasoactive proteins, which leads to vasodilation. This then allows increased sodium excretion from the kidneys and so a reduced extra-cellular volume. This offloads the patient and reduces symptoms.

When can it be used?

  • Patients in NYHA categories II to IV (there is less evidence on patients in class IV) and
  • LV ejection fraction of 35% or less and
  • Who are already taking a stable dose of ACEi or ARB.
  • It should be started by a specialist.

Does it work?

The study compared it to enalapril. It showed reduced cardiovascular death and all-cause mortality. It also reduced hospitalisation for heart failure.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"LocumDeck is so good and so intuitive that I am lost for words and utterly filled with glee.

It can send an email confirming the sessions that are booked and creates and emails invoices direct to the practice for you. These contain links to your beautifully laid out ‘credentials’ page with all your relevant documents, and a model contract that is all ready for you to accept or edit.

It automatically produces and sends the locum form A, and will produce locum form B. It also acts as the calendar... And it all happens automatically. It is really less than a minute to invoice and do the pension forms, with everything calculated perfectly."

Dr Annette Steele

See the full list of features within our NASGP membership plans

Membership